Presentation to include new data in triple-negative disease, a breast cancer subtype with poor outcomes and limited viable treatment options ATNM-400 overcomes HER2 therapy resistance and represents a ...

- ATNM-400 targets a novel, non-PSMA antigen implicated in disease biology withcontinued expression following androgen receptor pathway inhibitor (ARPI) therapy and 177Lu-PSMA-617 therapy, enabling ...

SAN DIEGO--(BUSINESS WIRE)--Onchilles Pharma, a private biotech company developing cancer therapeutics that leverage a novel innate immune mechanism of action for potent and selective cancer killing, ...

July 24, 2007 (Sydney) -- The novel integrase inhibitor raltegravir combined with tenofovir (TFV) and lamivudine (3TC) demonstrated comparable safety to efavirenz (EFV)/TFV/3TC in treatment-naive ...

From CRISPR and artificial intelligence to an old, once-rejected drug, the arsenal of potential weapons against antibiotic resistance is, thankfully, growing at last. The latest: a synthetic ...

Data support advancement of GS-6791 into clinical testing in patients with inflammatory diseases; first-in-human Phase 1 trial in healthy volunteers is ongoing Data are being presented at the European ...

Despite its promising therapeutic efficacy in patients with narcolepsy type 1, the previously reported orally available orexin OX2 receptor (OX2R) agonist TAK-994 has also demonstrated off-target ...

NEW YORK, Dec. 1, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), a leader in the development of differentiated targeted radiotherapies, today announced compelling ...

NEW YORK, Oct. 24, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of differentiated targeted radiotherapies, today ...